Evidence map›Paper›PMID 38789997›Full record

Trial reportBMC oral health2024

Efficacy of Danzhixiaoyao tablets combined with methylcobalamin tablets in the treatment of burning mouth syndrome: an open-label, randomized controlled trial.

Ya Gao, Jingwen Yang, Huimin Sun, Haiwen Zhou

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC oral health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ya Gao *Department of Oral Mucosal Diseases, Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingwen Yang *Department of Oral Mucosal Diseases, Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huimin SunDepartment of Oral Mucosal Diseases, Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Haiwen ZhouDepartment of Oral Mucosal Diseases, Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China. haiwen39@126.com.

Funding

National Key Research and Development Program of China 81170968Traditional Chinese Medicine Scientific Research Project of Shanghai Municipal Health Commission in 2020-2021 2020LP023
6 · The paper itself

Abstract

objectivesThis randomized controlled trial compared the efficacy and tolerability of danzhixiaoyao pills in the accurate treatment of patients with burning mouth syndrome (BMS).

methodCollect a total of 78 patients (75 female patients and 3 male patients) from the oral mucosa department who were considered eligible fromOctober 2020 to October 2022.The patients were randomized and divided into trial group and control group.The trail group received danzhixiaoyao pills and mecobalamine tablets while the control group was given mecobalamine tablets.The Visual Analogue Scale (VAS), Beck Anxiety Inventory(BAI), Beck Depression Inventory (BDI), Oral Health Impact Profile (OHIP-14), Traditional Chinese medicine(TCM) syndrome integral and adverse reactions were performed at baseline and after 2, 4, and 6 weeks of treatment. Descriptive statistics, including the Wilcoxon rank-sum test and the Chi-square test for median comparisons between different times, were used.

result1.After treatment, the VAS, BDI,OHIP-14, and TCM syndrome integral in the trial group had a significant decrease than the control group(P< 0.05).However, there was no statistical difference in the BAI scores between the two groups (P> 0.05). 2.According to the efficacy determination criteria , the total effective rate of the test group was 73.68% , the control group was 52.94% and the recurrence rate was 0. There was a significant difference between the two groups (Z=-2.688, P < 0.05). The results showed that the curative effect of test group was better than that of control group.3. No adverse effects occurred in patients in either group.

conclusionDanzhixiaoyao pills has demonstrated to have a positive effect in relieving BMS symptoms and in improving a patient's overall quality of life with no AEs compared with the control group. The efficacy evaluation systems that can be verified and complementary in this study provide a perfect, effective and referential evaluation system for the use of Chinese patent medicine in the treatment of oral mucosal diseases.

trial registrationRegistry name: Chinese Clinical trail Registry Registration number: ChiCTR2000038189 Date of Registration: 2020-09-13 Please visit ( https://www.chictr.org.cn/showproj.html?proj=61462 ) to the protocol.

Indexed as

Burning Mouth SyndromeDrugs, Chinese HerbalTabletsVitamin B 12AdultAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedTreatment Outcomedanzhi xiaoyaoDrugs, Chinese HerbalmecobalaminTabletsVitamin B 12Anxietyburning mouth syndromeChinese patent medicineChinese traditional treatmentDanzhixiaoyao pillsDepressionSyndromeTraditional Chinese medicine(TCM)VAS

Identifiers

PMID38789997
PMCPMC11127324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.